Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? a meta-analysis is needed! [11]

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5673-5674

  Collette, Laurence ^a   Buyse, Marc ^b   Burzykowski, Tomasz ^c  

^a EORTC DATA CENTER   (Belgium)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC AGENT; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MARKER; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTORY PERIOD; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MITOXANTRONE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 37649009642     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5268     Document Type: Letter

References (11)

1. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965-3970, 2007
2. Prentice RL: Surrogate endpoints in clinical trials: Definitions and operational criteria. Stat Med 8:431-440, 1989
3. Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints in chronic disease. Stat Med 11:167-178, 1992
4. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006
5. Freedman LS: Confidence intervals and statistical power of the 'validation' ratio for surrogate or intermediate endpoints. J Stat Plan Inference 96:143-153, 2001
6. Buyse M, Molenberghs G: Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029, 1998
7. Molenberghs G, Buyse M, Geys H, et al: Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 23:607-625, 2002
8. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67, 2000
9. Buyse M, Vangeneugden T, Bijnens L, et al: Validation of biomarkers as surrogates for clinical endpoints, in Bloom JC, Dean RA (eds): Biomarkers in Clinical Drug Development, Marcel Dekker, New York, NY, 2003, pp 149-168
10. Collette L, Burzykowski T, Carroll K, et al: Is prostate-specific antigen a valid surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol 23:6139-6148, 2005
11. Burzykowski T, Buyse M: Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 5:173-186, 2006